SARS-CoV-2 rS Nanoparticle Vaccine Uses, Dosage, Side Effects and more
SARS-CoV-2 rS Nanoparticle Vaccine is a SARS-CoV-2 rS vaccine candidate and was shown to have high immunogenicity in studies. The vaccine is created from the genetic sequence of COVID-19 and the antigen derived from the virus spike protein is generated using recombinant nanoparticle technology. The vaccine was developed and tested by Novavax. As of May 2020, the company is pursuing a Phase 1 clinical trial (NCT04368988) to test the vaccine.
| Trade Name | SARS-CoV-2 rS Nanoparticle Vaccine |
| Generic | NVX-CoV2373 |
| NVX-CoV2373 Other Names | SARS-CoV-2 rS Nanoparticle Vaccine |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
